NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

COLONIE — Latham's AngioDynamics is alleging that a major competitor in the medical device market, C.R. Bard, is violating anti-trust laws in the sale of its catheters. In a lawsuit filed in U.S.

Medical device company C.R. Bard (BCR +0.00%) plans to acquire Medafor, a privately held developer and supplier of plant-based hemostatic agents such as Arista MPH Hemostat, which can control bleeding ...

This post is from Forbes partner Narrative Science. Wall Street is expecting higher profit for C.R. Bard (BCR) when the company reports its third quarter results. The consensus estimate is calling for ...

NEW YORK (Reuters) - U.S. medical equipment supplier Becton Dickinson and Co (BDX.N) will acquire C R Bard Inc (BCR.N), in a $24 billion (£18.72 billion) cash-and-stock deal, adding Bard's devices to ...

Shares of C.R. Bard Inc.BCR climbed 2.1% to $190.22, following the signing of a definitive agreement to acquire Kobayashi Pharmaceutical's 50% stake in Medicon. Medicon is a joint venture formed by ...

Analysts expect higher profit for C.R. Bard when the company reports its first quarter results on Thursday, April 23, 2015. The consensus estimate is calling for profit of $2.07 a share, reflecting a ...

FRANKLIN LAKES, N.J. (AP) -- Medical technology firm Becton, Dickinson and Co. says it has reached an agreement to buy competitor C.R. Bard Inc. in a cash-and-stock deal worth $24 billion. The deal ...

Becton, Dickinson and Co. said on Sunday that it would acquire C. R. Bard Inc. for $24 billion in the latest merger of medical-supplies manufacturers. The deal values C.R. Bard at $317 per share, a 25 ...